Xeno Biosciences is developing XEN-101, a first-in-class oral treatment for obesity that mimics the microbiome alterations associated with gastric bypass surgery. This investigational therapy aims to provide a non-surgical weight loss solution with demonstrated efficacy in preclinical and early human studies, addressing the limited options available for managing obesity and its related metabolic diseases.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity is a chronic, relapsing disease with limited effective treatment options beyond bariatric surgery, impacting metabolic, biomechanical, and psychosocial health. Current non-surgical interventions often lack the efficacy needed to produce significant and sustained weight loss.
Solution
Xeno Biosciences is developing XEN-101, a first-in-class oral therapy designed to treat obesity by replicating the beneficial microbiome alterations observed after gastric bypass surgery. This investigational drug offers a non-surgical approach to weight loss, potentially providing a more accessible and less invasive option for managing obesity and related metabolic disorders. Preclinical and early human studies have shown promising efficacy with limited side effects.
Target Audience
The primary target audience includes individuals suffering from obesity and related metabolic diseases who are seeking non-surgical weight loss solutions.
Features
- Oral formulation for convenient administration
- Engineered to mimic microbiome changes induced by gastric bypass
- Demonstrated significant weight loss effects in animal models
- Planned evaluation in a Phase I clinical trial